2017
Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group
Wu CC, Econs MJ, DiMeglio LA, Insogna KL, Levine MA, Orchard PJ, Miller WP, Petryk A, Rush ET, Shoback DM, Ward LM, Polgreen LE. Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. The Journal Of Clinical Endocrinology & Metabolism 2017, 102: 3111-3123. PMID: 28655174, DOI: 10.1210/jc.2017-01127.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationDisease complicationsConsensus guidelinesHigher bone mineral densityRare metabolic bone diseaseCranial nerve impingementManagement of patientsEvidence-based guidelinesStrength of recommendationsCharacteristic radiographic findingsExpert opinion-based guidelinesQuality of evidenceStandard of careExpert consensus guidelinesBone mineral densityMetabolic bone diseaseOpinion-based guidelinesSevere infantile formNerve impingementRecommendations AssessmentSupportive therapyRadiographic findingsAreas of diagnosisCell transplantationDental disease
2015
Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease
Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, Simpson CA, Sterpka J, Dubrow R, Zhang JH, Carpenter TO. Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 3625-3632. PMID: 26176801, PMCID: PMC4596038, DOI: 10.1210/jc.2015-2199.Peer-Reviewed Original ResearchConceptsSevere dental diseaseHospital research unitDental diseaseDisease severityXLH patientsMajor long-term morbidityActive vitamin D metaboliteAdult XLH patientsLong-term morbidityVitamin D metabolitesAdult lifeMultiple logistic regressionRadiographic skeletal surveySignificant predictorsProportion of adultsConventional therapyD metabolitesSkeletal surveyLower riskExposure variablesLogistic regressionDiseaseEnthesopathySkeletal deformitiesTreatment variables
2010
Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status
Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM. Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e352-e357. PMID: 20685863, PMCID: PMC2968736, DOI: 10.1210/jc.2010-0589.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedBone Density Conservation AgentsCalcitriolChildCircadian RhythmEnzyme-Linked Immunosorbent AssayFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic Diseases, X-LinkedGlucuronidaseHumansKlotho ProteinsMaleMiddle AgedParathyroid HormonePhosphatesVitamin DConceptsSerum KlothoSerum FGF23Higher klotho levelsHospital research unitRenal phosphate handlingAcademic medical centerEffect of treatmentFibroblast growth factorKlotho levelsPTH secretionMedical therapySoluble KlothoDihydroxyvitamin DFGF23 regulationPhosphate handlingMedical CenterFGF23KlothoXLHCircadian variationGrowth factorPTHAdultsHypophosphatemiaTherapy
2002
Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism
Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 4946-4951. PMID: 12414855, DOI: 10.1210/jc.2001-011814.Peer-Reviewed Original ResearchConceptsBone lossIL-6sRTotal femurIL-6IL-6 soluble receptorPrimary hyperparathyroidism resultsYearly bone lossSubset of patientsUntreated hyperparathyroidismDisease activityPrimary hyperparathyroidismUpper tertileCytokine axisHyperparathyroidismSoluble receptorPatientsBiochemical markersClassical biochemical markersWhole groupFemurPredict rateGreater rateRecent studiesTertileGroup
1997
Parathyroid Hormone Increases Circulating Levels of Fibronectin in Vivo: Modulating Effect of Ovariectomy
Sun B, Mitnick M, Eielson C, Yao G, Paliwal I, Insogna K. Parathyroid Hormone Increases Circulating Levels of Fibronectin in Vivo: Modulating Effect of Ovariectomy. Endocrinology 1997, 138: 3918-3924. PMID: 9275082, DOI: 10.1210/endo.138.9.5421.Peer-Reviewed Original ResearchConceptsLevels of fibronectinEffect of PTHAbility of PTHHuman PTHAdult female Sprague-Dawley ratsFemale Sprague-Dawley ratsCultured fetal rat bonesDiminished bone formationEstrogen-deficient stateHuman PTH-(1-34) infusionSprague-Dawley ratsFN productionFetal rat boneBisphosphonate APDHPTH groupPTH infusionCirculating LevelsAlzet minipumpsEstrogen deficiencyParathyroid hormoneEstrogen withdrawalBone resorptionAnabolic propertiesROS 17/2.8 cellsEffective agonistRole of c‐Src in cellular events associated with colony‐stimulating factor‐1‐induced spreading in osteoclasts
Insogna K, Tanaka S, Neff L, Horne W, Levy J, Baron R. Role of c‐Src in cellular events associated with colony‐stimulating factor‐1‐induced spreading in osteoclasts. Molecular Reproduction And Development 1997, 46: 104-108. PMID: 8981371, DOI: 10.1002/(sici)1098-2795(199701)46:1<104::aid-mrd16>3.0.co;2-2.BooksMeSH KeywordsActininAnimalsBone MarrowBone Marrow CellsCalcitriolCell SizeCells, CulturedCytoskeletonFemaleHumansMacrophage Colony-Stimulating FactorMiceMicroscopy, ConfocalOsteoblastsOsteoclastsOsteoporosisPhosphatidylinositol 4,5-DiphosphatePhosphorylationProtein Processing, Post-TranslationalProto-Oncogene Proteins pp60(c-src)RatsSignal TransductionConceptsOsteoclast-like cellsNeonatal rat osteoclastsRat osteoclastsCSF-1 treatmentMonoclonal antibodiesC-fmsCSF-1C-SrcCellular eventsWestern blot analysisTime-dependent increaseMurine bone marrowBasal abnormalitiesBone marrowConfocal microscopic studiesPIP2 contentSignificant doseReceptor tyrosine kinasesOsteoclastsTyrosine kinase activityC-Src kinase activityCell-signaling eventsTargeted disruptionTreatmentIntrinsic tyrosine kinase activity
1994
Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia
Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. The Journal Of Clinical Endocrinology & Metabolism 1994, 78: 1378-1383. PMID: 8200940, DOI: 10.1210/jcem.78.6.8200940.Peer-Reviewed Original ResearchConceptsHypophosphatemic ricketsFrequency of hyperparathyroidismMean iPTH valueNephrogenous cAMP excretionPathogenesis of nephrocalcinosisInitiation of therapyVitamin D preparationsGroup of patientsOnset of treatmentExaggerated secretionParathyroid statusIPTH valuesTertiary hyperparathyroidismParathyroid functionUntreated patientsOccasional complicationCAMP excretionHyperparathyroidismPhosphopenic ricketsD preparationsPatientsControl individualsRicketsIntact hormoneNocturnal rise
1992
A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets
Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 879-885. PMID: 1517380, DOI: 10.1210/jcem.75.3.1517380.Peer-Reviewed Original ResearchConceptsSymptomatic adultsOral phosphateOsteoid volumeCessation of therapyUrinary calcium excretionSymptomatic adult patientsMean serum phosphateDihydroxyvitamin D3 therapyMineral apposition rateCalcium excretionD3 therapyRenal insufficiencyTertiary hyperparathyroidismAdult patientsDrug regimenJoint painMost patientsPretreatment serumProspective trialClinical courseSerum phosphateSymptom scoresBone biopsyCombined administrationCurrent treatmentSynthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo
Weir E, Terwilliger G, Sartori L, Insogna K. Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo. Calcified Tissue International 1992, 51: 30-34. PMID: 1393774, DOI: 10.1007/bf00296214.Peer-Reviewed Original ResearchConceptsBovine parathyroid hormoneSerum calciumParathyroid hormone-like proteinDaily subcutaneous injectionsPotent bone-resorbing agentHormone-related proteinDose-dependent increaseDry bone weightHighest dose levelHormone-like proteinBone-resorbing agentsBone dry weightLow dosage levelsHumoral hypercalcemiaParathyroid hormoneDihydroxyvitamin DMale SpragueDawley ratsSubcutaneous injectionHuman PTHrPBone calciumAnabolic agentsPTHrP actionDose levelsHigh doses
1991
Treatment of Sarcoidosis-Associated Hypercalcemia With Ketoconazole
Bia M, Insogna K. Treatment of Sarcoidosis-Associated Hypercalcemia With Ketoconazole. American Journal Of Kidney Diseases 1991, 18: 702-705. PMID: 1962657, DOI: 10.1016/s0272-6386(12)80613-5.Peer-Reviewed Original ResearchConceptsAngiotensin-converting enzyme levelsACE levelsSide effectsLong-term side effectsDihydroxyvitamin D levelsLiver function testsSymptom-free intervalSerum ACE levelsSerum testosterone levelsSerum cortisol levelsLong-term usePatient's hypercalcemiaCorticosteroid treatmentDisease activityKetoconazole therapySerum creatinineFunction testsPersistent elevationD levelsRapid recurrenceCalcium metabolismKetoconazole treatmentTestosterone levelsHypercalcemiaLarge dose
1990
Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calcium
Carpenter T, Insogna K, Boulware S, Mitnick M. Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calcium. The Journal Of Pediatrics 1990, 116: 252-257. PMID: 2299496, DOI: 10.1016/s0022-3476(05)82883-5.Peer-Reviewed Original Research
1988
Enhanced Production Rate of 1,25-Dihydroxyvitamin D in Sarcoidosis*
INSOGNA K, DREYER B, MITNICK M, ELLISON A, BROADUS A. Enhanced Production Rate of 1,25-Dihydroxyvitamin D in Sarcoidosis*. The Journal Of Clinical Endocrinology & Metabolism 1988, 66: 72-75. PMID: 3335611, DOI: 10.1210/jcem-66-1-72.Peer-Reviewed Original Research
1987
Concerning the Pathogenesis of Idiopathic Hypercalciuria1
Broadus AE, Burtis WJ, Oren DA, Sartori L, Gay L, Ellison AF, Insogna KL. Concerning the Pathogenesis of Idiopathic Hypercalciuria1. Contributions To Nephrology 1987, 58: 127-136. PMID: 3691116, DOI: 10.1159/000414502.Books
1986
Frequency and partial characterization of adenylate cyclase‐stimulating activity in tumors associated with humoral hypercalcemia of malignancy
Stewart A, Insogna K, Burtis W, Aminiafshar A, Wu T, Weir E, Broadus A. Frequency and partial characterization of adenylate cyclase‐stimulating activity in tumors associated with humoral hypercalcemia of malignancy. Journal Of Bone And Mineral Research 1986, 1: 267-276. PMID: 2845726, DOI: 10.1002/jbmr.5650010305.Peer-Reviewed Original ResearchConceptsAdenylate cyclase-stimulating activityCyclase-stimulating activityHumoral hypercalcemiaTumor extractsSyndrome of HHMBone-resorbing activityNonmalignant tissue samplesControl tumorsHumoral factorsControl groupTumorsTissue samplesHypercalcemiaPatientsMalignancyTissue culture mediumHigh-performance liquid chromatographyHHMLarge groupCulture mediumLiquid chromatographyGroupSyndromeActivity
1985
Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary Hyperparathyroidism
Insogna K, Mitnick M, Stewart A, Burtis W, Mallette L, Broadus A. Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary Hyperparathyroidism. New England Journal Of Medicine 1985, 313: 1126-1130. PMID: 2995810, DOI: 10.1056/nejm198510313131805.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismParathyroid functionParathyroid hormone-vitamin D axisAutonomous parathyroid functionNephrogenous cyclic AMPImmunoreactive parathyroid hormoneNormal dietary intakeExtracellular calcium concentrationParathyroid hormone 1Calcium excretionCalcium intakeUnselected patientsSerum levelsParathyroid hormoneDihydroxyvitamin DDietary calciumPlasma levelsDietary intakePhysiologic amountsHyperparathyroidismPatientsHormone 1Calcium concentrationCyclic AMPSignificant reductionElevated Production Rate of 1,25-Dihydroxyvitamin D in Patients with Absorptive Hypercalciuria*
INSOGNA K, BROADUS A, DREYER B, ELLISON A, GERTNER J. Elevated Production Rate of 1,25-Dihydroxyvitamin D in Patients with Absorptive Hypercalciuria*. The Journal Of Clinical Endocrinology & Metabolism 1985, 61: 490-495. PMID: 2991323, DOI: 10.1210/jcem-61-3-490.Peer-Reviewed Original ResearchConceptsAbsorptive hypercalciuriaMicrograms/dayNormal subjectsMetabolic clearancePlasma radioactivityMean steady-state concentrationMCR valuesHypercalciuric patientsCalcium intakeDihydroxyvitamin DSerial measurementsHypercalciuriaPatientsConstant infusionConflicting resultsClearanceSteady-state concentrationsElevations in Circulating 1,25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia*
ROSENTHAL N, INSOGNA K, GODSALL J, GAC A, SMALDONE L, WALDRON J, STEWART A. Elevations in Circulating 1,25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia*. The Journal Of Clinical Endocrinology & Metabolism 1985, 60: 29-33. PMID: 3871092, DOI: 10.1210/jcem-60-1-29.Peer-Reviewed Original ResearchConceptsDihydroxyvitamin DBone marrow biopsyElevated plasma levelsImmunoreactive PTH levelsUrinary cAMP excretionVitamin D metabolitesAdenylate cyclase-stimulating activityCyclase-stimulating activityPTH levelsRadionuclide scansMedical therapyMalignant lymphomaSerum calciumSurgical excisionMarrow biopsyCertain patientsRapid normalizationSplenic lymphomaSystemic mediatorsUrinary excretionD metabolitesPlasma levelsCAMP excretionTumor extractsPatients
1984
Evidence for Disordered Control of 1,25-Dihydroxyvitamin D Production in Absorptive Hypercalciuria
Broadus A, Insogna K, Lang R, Ellison A, Dreyer B. Evidence for Disordered Control of 1,25-Dihydroxyvitamin D Production in Absorptive Hypercalciuria. New England Journal Of Medicine 1984, 311: 73-80. PMID: 6330548, DOI: 10.1056/nejm198407123110201.Peer-Reviewed Original ResearchConceptsAbsorptive hypercalciuriaCalcium intakeDietary calcium intakeDihydroxyvitamin D productionRenal phosphate handlingDihydroxyvitamin DPhosphate handlingSuppression testHypercalciuriaPatientsD productionShort-term increaseSyndromeIntakePresent studyInitial levelLarge majorityPrevious studiesEvidenceAbnormalitiesWeeksBiochemical and Histomorphometric Characterization of a Rat Model for Humoral Hypercalcemia of Malignancy*
INSOGNA K, STEWART A, VIGNERY A, WEIR E, NAMNUM P, BARON R, KIRKWOOD J, DEFTOS L, BROADUS A. Biochemical and Histomorphometric Characterization of a Rat Model for Humoral Hypercalcemia of Malignancy*. Endocrinology 1984, 114: 888-896. PMID: 6546543, DOI: 10.1210/endo-114-3-888.Peer-Reviewed Original ResearchConceptsTumor-bearing animalsBone-resorbing activityHumoral hypercalcemiaDay 13Dihydroxyvitamin D valuesFractional phosphorus excretionQuantitative bone histomorphometryAction of PTHImmunoreactive PTH levelsTumor-bearing groupLeydig cell tumorMale Fisher ratsBone cell functionPTH levelsNephrogenous cAMPDihydroxyvitamin DTumor transplantationCell tumorsBone resorptionBone histomorphometryRat modelTumor groupControl animalsFisher ratsMarked suppressionA Consideration of the Hormonal Basis and Phosphate Leak Hypothesis of Absorptive Hypercalciuria*
BROADUS A, INSOGNA K, LANG R, MALLETTE L, ORENLANG D, GERTNER J, KLIGER A, ELLISON A. A Consideration of the Hormonal Basis and Phosphate Leak Hypothesis of Absorptive Hypercalciuria*. The Journal Of Clinical Endocrinology & Metabolism 1984, 58: 161-169. PMID: 6546292, DOI: 10.1210/jcem-58-1-161.Peer-Reviewed Original ResearchConceptsAbsorptive hypercalciuriaNormal subjectsCalcium excretionOral calcium tolerance testCalcium tolerance testFractional calcium excretionRenal calcium leakRenal phosphate thresholdHypercalciuric patientsMild hypercalcemiaNephrogenous cAMPCalcium intakeDihydroxyvitamin DPathophysiological basisTolerance testPlasma concentrationsUrine collectionStone diseaseCalcium leakPatientsControl groupSevere patternSignificant negative correlationHormonal basisFindings 1